$VERUAug 10, 2026, 10:30 AMAI processed
VERU: Enobosarm+semaglutide Phase 2b PLATEAU fully enrolled (239); interim readout on track Q1 2027; USPTO allowance
AI Summary
Veru says its Phase 2b PLATEAU trial of enobosarm added to semaglutide is fully enrolled at 239 patients (target 200); an interim DXA analysis of lean and fat mass after 32 weeks is on track for Q1 2027 and final topline data is expected in Q4 2027 (primary endpoint: % change in total body weight at 68 weeks). The company also announced a clinical supply agreement with Novo Nordisk, received a USPTO Notice of Allowance for a US patent covering enobosarm+semaglutide regimens (expected protection to at least Oct 2044), and reported Q3 cash of $23.9M and a net loss of $7.0M (‐$0.30) for the quarter.
Positives
- Phase 2b PLATEAU study fully enrolled with 239 patients (exceeded 200-patient target)
- Interim DXA analysis (lean and fat mass) on track for Q1 2027; topline expected Q4 2027
- USPTO issued Notice of Allowance for key US patent covering enobosarm plus semaglutide (expected protection to at least Oct 3, 2044)
Negatives
- Operating loss from continuing operations increased to $7.7M in the quarter (from $7.5M prior year)
- Cash, cash equivalents and restricted cash were $23.9M as of June 30, 2026
- Final topline PLATEAU results not expected until Q4 2027 (long timeline to pivotal data)